Chiesi to buy KalVista in $1.9bn deal
Italian biopharmaceutical firm Chiesi Group has struck a definitive agreement to acquire listed KalVista Pharmaceuticals in an all-cash transaction valued at approximately $1.9bn. The transaction has secured unanimous approval from both corporate boards and is slated to close in the third quarter of 2026, subject to customary regulatory clearances and the tender of a majority of shares. Under the terms…